US19459J1043
US19459J1043
Collegium Pharmaceutical, Inc.
Loading chart...
Elevated Business & Solvency Risk
Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 50/100).
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).
Beta (Market Relation)
0.73x
DefensiveVolatility (5Y p.a.)
40.6% p.a.
5-Year HorizonMax Drawdown (5Y)
-56.2%
5-Year HorizonSharpe Ratio
-0.02
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -33.3% |
| 3 Years | 40.8% | -56.2% | -0.11 | -2% |
| 5 Years | 40.6% | -56.2% | -0.02 | +1.7% |
| 10 Years | 52.9% | -65.2% | -0.01 | +2% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 390%.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -65.2% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
1 ISS Score: 1 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
2 ISS Score: 2 / 10
Short Ratio
6.65